Will Verastem, Inc. (NASDAQ:VSTM) be growing after Earnings Report?


Verastem, Inc. (NASDAQ:VSTM) moved up 2.74% and closed its last trading session at $1.5. This Medical Sector stock currently has the Market Capitalization of 55.5 Million. The Average Volume for the stock is measured as 215.89 Million. The Stock has a 52-Week High of $1.93 and 52-Week Low of $1.05 following the dates, it touched its 52-Week High on Apr 28, 2016 and 52-Week Low on Dec 6, 2016. Currently, the Return on Assets value for the trailing twelve months is -36.6% with the Return on Equity and Return on Investment of -39.6% and 0% respectively. This firm currently has YTD (year to date) performance of 33.93 Percent which is awesome. The Short Ratio for the stock is 0.59.

Verastem, Inc. (NASDAQ:VSTM) Price to Earnings (P/E) ratio is 0. EPS or Earning per Share stands at $-0.99. The TTM operating margin is 0 percent.

Verastem, Inc. (NASDAQ:VSTM) reports its Earnings on Thu 9 Mar (10 days ago). The estimated EPS for the current quarter is said to be $-0.27. Following Earnings result, share price were UP 7 times out of last 17 Qtrs. The stock has added about 32.7% since it reported its last earnings. The Closing price of Verastem, Inc. (NASDAQ:VSTM) at Last Earnings was $ as compared to the previous closing price of $1.5. The Predicted Move on the 7th day after Verastem, Inc. (NASDAQ:VSTM) will release its earnings at about 8%.

By Looking at Earnings History, Out of 12 Quarters when the Earnings were reported, Verastem, Inc. (NASDAQ:VSTM) beats earnings by 66%, The Stock Missed Earnings  4  times and has met earnings  0 times.

Company Profile:

Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing drugs targeting cancer stem cells (CSCs). Its programs target the focal adhesion kinase (FAK) and the PI3K/mTOR signaling pathways. The company’s product candidate FAK inhibitor, VS-6063, is in Phase 1 study in combination with PD-1 inhibitor pembrolizumab and gemcitabine for pancreatic cancer; a Phase Ib clinical trial in combination with paclitaxel for patients with ovarian cancer; a Phase II study in patients with non-small cell lung cancer; a Phase II trial preceding surgery in mesothelioma; and a Phase 1/1b clinical trail in combination with avelumab in patients with ovarian cancer, as well as a combination trial of VS-6063 and VS-5584 in patients with relapsed mesothelioma. It is also developing FAK inhibitor, VS-4718 that is in Phase 1, single-agent, dose escalation trial in patients with advanced cancers; and a Phase 1, dose-escalation clinical trial in combination with gemcitabine and nab-paclitaxel in patients with advanced solid tumors, as well as a Phase 1, dose-escalation clinical trial of PI3K/mTORC1/2 inhibitor, VS-5584, in patients with advanced non-hematologic malignancies or lymphoma. The company has license agreement with Whitehead Institute for Biomedical Research; The Scripps Research Institute; and Pfizer, Inc. Verastem, Inc. was founded in 2010 and is based in Needham, Massachusetts.